A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.
(Image credit: ©Ralf/AdobeStock)
A class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, has been issued after Laboratoires Théa notified the Medicines and Healthcare products Regulatory Agency (MHRA) of an event during manufacturing that may increase the risk of microbial contamination in the product.1 This recall is precautionary and there are currently no adverse events reported.
Batch number 4V64 of Zaditen 0.25 mg/ml, eye drops, solution, was first distributed January 27, 2025, and has an expiration date of September 30, 2026.
Due to the recall, healthcare professionals are advised from the MHRA to stop supplying the batch immediately and to quarantine all stock and return it to the supplier it was received by. A confirmed 11,360 packs of the affected batch have been distributed, according to Thea Pharmaceuticals. At the time of this article, there are no reported adverse events or product quality complaints received.
For patients, the MHRA said no further action is required, “as this is a Pharmacy and Wholesaler level recall related to a specific batch of Zaditen 0.25 mg/ml, eye drops, solution,” according to a press release. Should any suspected adverse reactions arise, they can be reported via the MHRA Yellow Card scheme.1
For stock control enquiries:1
For more information of medical information, call 0345 521 1290 (option 3) or email thea-pharma@medinformation.co.uk.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.